Cytokinetics (CYTK) EVP Andrew Callos Exercises Options and Sells Shares

What Happened
Andrew Callos, EVP & Chief Commercial Officer of Cytokinetics (CYTK), exercised 14,000 stock options at $23.26 per share on 2026-07-30 (cost $325,640) and immediately sold the 14,000 shares in the open market at $79.88 per share for $1,118,320. The filing also records the derivative position related to the options as disposed (typical when options are exercised). After the transactions, gross sale proceeds were $1,118,320 and the difference between sale proceeds and exercise cost was about $792,680 before fees and taxes. This is an option exercise followed by an immediate sale (routine insider sale rather than a purchase).

Key Details

• Transaction date: 2026-07-30
• Option exercise: 14,000 shares at $23.26 each — total cost $325,640 (Transaction code M).
• Open-market sale: 14,000 shares at $79.88 each — total proceeds $1,118,320 (Transaction code S).
• Derivative disposition: 14,000 option-related derivative reported disposed at $0 (reflects termination of the option on exercise).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: Options vest over 4 years from the grant date — 1/4 after one year, then monthly vesting over the next 36 months (subject to continued employment).
• Filing timeliness: Reported with the same transaction date (filed 2026-07-30), indicating a timely Form 4.

Context
Because the exercised shares were sold the same day, this is effectively a cashless exercise and sale — common when insiders exercise options to monetize vested awards or cover tax/option costs. Such sales are routine and do not by themselves indicate company-wide sentiment; purchases typically convey a stronger bullish signal.